Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Dec 6:6:1-16.
doi: 10.2147/RRU.S40034.

Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life

Jyotsna Jayarajan  1 , Sidney B Radomski  1
Affiliations
Review

Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life

Jyotsna Jayarajan et al. Res Rep Urol. .

Abstract

Introduction: Overactive bladder (OAB) is a prevalent condition that has a significant impact on quality of life. The usual treatment approach is both behavioral and pharmacological. The first-line pharmacological treatment commonly utilizes anticholinergic agents, which may be limited by their tolerability, efficacy, and long-term compliance. Developments in elucidating the pathophysiology of OAB and alternative targets for pharmacological therapy have led to newer agents being developed to manage this condition. These agents include mirabegron and botulinum toxin, which have alternate mechanism of action and avoid the anticholinergic side effects.

Objectives: To provide an update for clinicians managing OAB with an overview of the existing and newer medical options for OAB, including pharmacology, efficacy, side-effect profile, tolerability, and impact on patient quality of life.

Methods: PubMed and Medline were searched for randomized controlled drug trials in adults with OAB, meta-analyses of medical therapy for OAB, and individual drug names, including the keywords efficacy, tolerability, quality of life, and compliance. Nonhuman studies, pediatric trials, and those involving patients with neurogenic bladder dysfunction (with the exception of studies involving botulinum toxin A) were excluded.

Results: There is level 1, Grade A evidence to support the efficacy of anticholinergic drugs, botulinum toxin, and mirabegron for OAB. Long-term compliance with anticholinergic medications is limited. The mechanism of action, effectiveness, and side effects of these drugs are discussed, and where the data are available compared with other OAB medications.

Conclusion: Most of the anticholinergic agents have comparative efficacies and core side-effect profiles, with individual variations relating to their muscarinic receptor selectivity, pharmacokinetics, and metabolism. Newer agents, with alternative sites of action, such as mirabegron and botulinum toxin, provide additional treatment options for patients intolerant to or inadequately treated with anticholinergics.

Keywords: antimuscarinics; botulinum toxin; incontinence; mirabegron.

PubMed Disclaimer

References

    1. Abrams P, Cardozo L, Fall M, et al. Standardization Sub-Committee of the International Continence Society The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Urology. 2003;61(1):37–49. - PubMed
    1. Radomski SB, Barkin J. Medical management of overactive bladder. Can J Urol. 2012;19( Suppl 1):2–9. - PubMed
    1. Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc. 2000;48(4):370–374. - PubMed
    1. Christofi N, Hextall A. An evidence-based approach to lifestyle interventions in urogynaecology. Menopause Int. 2007;13(4):154–158. - PubMed
    1. Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci. 2008;9(6):453–466. - PMC - PubMed